Phaseline

Targets › GPR55

GPR55 (G protein-coupled receptor 55): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Psychiatry; next expected readout Dec 2026.

G protein-coupled receptor that binds to several ligands including 2-arachidonoyl lysophosphatidylinositol or lysophosphatidylglucoside with high affinity, leading to rapid and transient activation of numerous intracellular signaling pathways. Induces the Ca(2+) release from intracellular stores via ERK, the heterotrimeric G protein GNA13 and RHOA leading to morphological changes including cell rounding and stress…. (UniProt, Q9Y2T6)

Open in Phaseline: the race on GPR55, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Universidade do Sul de Santa CatarinaFull-spectrum CBG oil 30 mg/mL
Full-spectrum Cannabis extract containing cannabigerol (CBG), cannabidiol (CBD), and tetra
CNR1, CNR2, GPR55Phase 1Attention-Deficit/Hyperactivity Disorder (ADHD)Dec 2026

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD) (1)

Modalities

small molecule (1)

Companies

Universidade do Sul de Santa Catarina (1)

Related targets

CNR1 (1) CNR2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.